|
Wong HH, Halford S |
Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? |
Monday, October 5, 2015 |
The Lancet Oncology |
|
Rintoul RC, Treasure T, Macbeth F |
Multimodal treatment for malignant pleural mesothelioma |
Friday, November 6, 2015 |
The Lancet Oncology |
|
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. |
Lenvatinib, everolimus, and the combination in patients with metastatic ren... |
Wednesday, October 21, 2015 |
The Lancet Oncology |
|
Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, et al. |
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorour... |
Saturday, May 16, 2015 |
The Lancet Oncology |
|
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et ... |
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-p... |
Wednesday, May 20, 2015 |
The Lancet Oncology |
|
Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC |
Consensus on the management of intracranial germ-cell tumours |
Wednesday, September 16, 2015 |
The Lancet Oncology |
|
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sr... |
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in p... |
Wednesday, October 28, 2020 |
The Lancet Oncology |
|
Lamb AD, Bratt O |
Towards ""next-generation"" prostate cancer screening |
Saturday, November 14, 2015 |
The Lancet Oncology |
|
Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, G... |
Analysis of circulating tumor DNA to monitor metastatic breast cancer |
|
The New England Journal of Medicine |
|
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. |
Effect of mutation order on myeloproliferative neoplasms |
Thursday, February 12, 2015 |
The New England journal of medicine |
